New initiatives and partnerships point the way forward for antimicrobial resistance response

  28 February 2020

Over the past year, the UK’s leading role in the chemotherapy or caesarean sections are now global fight against antimicrobial resistance (AMR) has been given several boosts. Government initiatives and new private-sector partnerships mean the country is solidifying its position at the forefront of the challenge to develop new, innovative treatments for patients suffering life-threatening infections caused by antibiotic-resistant bacteria.
AMR occurs when microbial pathogens develop resistance to the effects of antibiotics. A small number of bacteria survive exposure to the drugs by evolving, often with multiple resistance mechanisms for different antibiotic types, meaning each subsequent infection becomes more difficult to treat, passing from patient to patient and spreading around the world.
The World Health Organization (WHO) has reported resistance rates to be growing at an alarming rate, even in countries with strong healthcare infrastructure and good antibiotic stewardship. A 2019 study found almost 50% of bacteria samples collected from public areas of London to be resistant to multiple antibiotic types.

Further reading: Open Access Government
Author(s): Open Access Government
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!